Previous 10 | Next 10 |
2023-08-15 08:02:50 ET More on Galecto Galecto an outperform at Oppenheimer on fibrosis assets catalysts Galecto stock rises 12% as GB1211 shows efficacy in liver disease patients in trial Galecto’s GB1211 to be studied for phase 2 trial in combination with pe...
BOSTON, Aug. 15, 2023 (GLOBE NEWSWIRE) -- Galecto, Inc. (NASDAQ: GLTO), a clinical-stage biotechnology company and world leader in galectin biology, focused on the development of novel treatments for fibrosis and cancer, today announced topline results from its Phase 2b GALACTIC-1 trial evaluatin...
2023-07-31 17:13:57 ET Galecto press release ( NASDAQ: GLTO ): Q2 GAAP EPS of -$0.41. Cash, cash equivalents, and investments as of June 30, 2023 were approximately $52.1 million. For further details see: Galecto GAAP EPS of -$0.41
Galecto, Inc. (NASDAQ: GLTO) is one of today's top gainers. The company's shares are currently up 21.12% on the day to $2.81. Galecto, Inc., a clinical-stage biotechnology company, develops molecules for the treatment of fibrosis, cancer, inflammation, and other related diseases. The company's...
2023-07-25 12:09:08 ET Gainers: Electra Battery Materials ( ELBM ) +72% . Bullfrog AI Holdings ( BFRG ) +38% . Kiniksa Pharmaceuticals ( KNSA ) +30% . Steakholder Foods ( STKH ) +25% . Galecto ( GLTO ) +23% . Rigetti Computin...
2023-07-25 10:18:59 ET Gainers: Bullfrog AI ( BFRG ) +35% . Carmell Therapeutics ( CTCX ) +32% . Kiniksa Pharmaceuticals ( KNSA ) +21% . Galecto ( GLTO ) +18% . Akebia Therapeutics ( AKBA ) +16% . Losers: NeuroOne Med...
2023-06-20 11:31:51 ET Oppenheimer has started Galecto ( NASDAQ: GLTO ) with an outperform rating saying that the biotech's fibrosis candidates have upcoming catalysts that could bode well for the company. The firm has a $12 price target (~323% upside based on Friday's close). ...
2023-06-20 09:13:00 ET Biotechnology company Galecto ( NASDAQ: GLTO ) said on Tuesday that it is set to join the Russell Microcap Index at the conclusion of the 2023 Russell index annual reconstitution, effective after June 26 market open. The membership in the Russell Mi...
BOSTON, June 20, 2023 (GLOBE NEWSWIRE) -- Galecto, Inc. (NASDAQ: GLTO), a clinical-stage biotechnology company and world leader in galectin biology focused on the development of novel treatments for fibrosis and cancer, today announced that it is set to join the Russell Microcap Index at the conc...
2023-06-16 17:39:00 ET Gainers: Kezar Life Sciences ( NASDAQ: KZR ) +6% . Telos Corporation ( TLS ) +4% . Dyne Therapeutics ( DYN ) +4% . Recursion Pharmaceuticals ( RXRX ) +4% . Berry Corporation ( BRY ) +4% . Losers: ...
News, Short Squeeze, Breakout and More Instantly...
BOSTON, May 01, 2024 (GLOBE NEWSWIRE) -- Galecto, Inc. (NASDAQ: GLTO), a clinical-stage biotechnology company focused on the development of novel treatments for cancer and fibrosis, today announced that the first patient has been enrolled in an investigator-initiated Phase 2 trial to evaluate GB1...
Morgan Advanced Materials Plc (MCRUF) is expected to report for Q4 2023 Security Federal Corp (SFDL) is expected to report for Q1 2024 Bank of the James Financial Group Inc. (BOTJ) is expected to report for Q1 2024 OMV AG (OMVJF) is expected to report $1.91 for Q1 2024 Pola Orbis ...